Frailty Does Not Hinder Dapagliflozin's HFrEF Impact: DAPA-HF Analysis

In fact, the greatest benefits were seen in the most-frail patients—not just for outcomes but also for quality of life.

Related Keywords

Denmark ,United Kingdom ,Scotland ,Alexandert Sandhu ,Boehringer Ingelheim Eli Lilly ,Astrazeneca ,Md University Of Glasgow ,Copenhagen University Hospital Rigshospitalet ,Md Stanford University School Of Medicine ,Drug Administration ,Eli Lilly ,Internal Medicine ,Stanford University School ,Kansas City Cardiomyopathy Questionnaire ,With Dapagliflozin ,